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Schistosomiasis is a widespread infection in Sub-Saharan 
Africa, which may affect the urinary and gastro-intestinal 
systems. The typical signs and symptoms are abdominal 
pain, diarrhoea, bloody stools and haematuria. The chron-
ic untreated infection could remain asymptomatic for 
years, but it can in some cases lead to severe complications 
such as liver damage, portal hypertension, chronic renal 
insufficiency and bladder cancer (Clerinx et al., 2011). The 
European Network on Imported Infectious Disease Sur-
veillance reports about 51,000 cases per year (Grobusch 
et al., 2003) mainly in travellers (Gautret, 2010). This is 
probably an underestimation of the real number of cas-
es, partially due to the lack of awareness and systematic 
screening among subjects at risk.
Praziquantel, the drug of choice for the treatment of 
schistosomiasis (Kramer et al., 2014), is not licensed for 
human use in Italy and needs to be imported on a named 
patient basis when charged on National Health Service 
provision. 
In Italy to date, all observed cases came from endemic 
areas, predominantly restricted to travellers returning 
from Africa and Asia (Grobusch et al., 2003; Poddighe et 
al., 2013) and asylum seekers, as recently described by 
Ceccarelli et al. (Ceccarelli et al., 2013). In previous years, 
cases of schistosomiasis used to be seen very rarely in 
the metropolitan area of Genoa. For example, in 2013 
and 2014 only 10 patients had been observed (5 patients/
year), as shown by a retrospective review of medical re-
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1st until June 31st 2015, about 291,302 people from the 
West Mediterraneansea campaign (Triton - Frontex) (Eu-
ropean Parliament website, 2015) were hosted in Italy. Of 
them, 1,025 were relocated to Genoa, the majority orig-
inating from Mali and Senegal, the countries with the 
highest prevalence of schistosomiasis (Lai et al., 2015). 
During this period, we observed a small but significant 
cluster of urinary schistosomiasis occurring in migrants 
coming to Europe through the Sicily Channel (Cenderel-
lo et al., 2016). From mid-July to the 10th August, 12 pa-
tients presented to clinical observation for different signs 
and symptoms (lymphadenopathy, hypereosinophilia, 
urticaria, fever and gross haematuria) at the two main 
general hospitals in Genoa (Ospedale Galliera and IRCCS 
San Martino-IST) and referred to Infectious Disease con-
sultants. Given the clinical and epidemiological context, 
a parasite search on fresh urine samples was performed 
and a diagnosis of schistosomiasis was obtained since 
all samples were positive for Schistosoma haematobium. 
Praziquantel was obtained and patients were treated 
with a dose of 40 mg/kg once-a-day (Kramer, 2014) with 
a regression of symptoms.
In a compact five-week time-frame the annual consump-
tion of praziquantel doubled abruptly, generating major 
supply problems, worsened by a period of summer holi-
days.
The aim of the present report is to focus attention on two 
aspects of the dramatic ongoing migration into Europe. 
First, host European countries need to provide a ready 
circulation of drugs for the treatment of tropical diseas-
es endemic in migrating populations, but otherwise rare 
in our geographic area. Aside from praziquantel, other 
drugs commonly used in the treatment of tropical diseases 
(e.g Strongyloidiasis, Filariasis) should be easily accessi-
ble. Drugs such as ivermectine, diethylcarbamazine and 
artesunate are not readily available in Italy and must be 
obtained abroad. Hospitality policies in Italy need to be 
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This work focused on Schistosoma spp. as a potential agent of gross haematuria in non endemic areas. 
This change in epidemiology is mainly due to recent migratory flows. Moreover it emphasized the need-
for cultural action (aimed at urologists, Dermatologists, General Practitioners and Emergency Medicine 
doctors) to provide the elements for a correct and timely diagnosis. But the most important issue raised 
by this paper is the call for a fast track supply of drugs (usually not available in Italy) to field operators for 
treating tropical diseases. 
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improved to include the registration of these drugs, that 
should be available and distributed within the National 
Health Services, thus improving patient treatment and 
health worker efficiency.
Second, there is a need for increased awareness for schisto-
somiasis among general practitioners, urologists, derma-
tologists and emergency doctors facing migrants from en-
demic areas. Not only schistosomiasis, but also other non 
endemic diseases could show an increased incidence over 
the next months or years in the European union. In addi-
tion to schistsomiasis, another likely example could be a 
rise in the incidence and prevalence of cutaneous and vis-
ceral leishmaniasis through the migratory flow from Syr-
ia and the Middle East (Mockenhaupt et al., 2016). These 
diseases are otherwise relatively rare in Europe, with the 
exception of the area surrounding the Mediteranean ba-
sin, and may have a sharp increase in new incident and 
prevalent cases (Mockenhaupt et al., 2016). Furthermore 
our clinical evidence is in line with recent data support-
ing the inclusion of schistosomiasis serology among the 
screening tests for migrants (Monge-Maillo et al., 2016). 
In fact, the early treatment of Schistosoma spp. infection 
not only reduces the risk of cancer development, but could 
also reverse some cases of otherwise already established 
liver fibrosis (Doehring-Schwerdtfegger et al., 1992). In 
particular, serologic assays have a significantly higher sen-
sitivity than microscopy (Lifson et al., 2002; Posey et al., 
2007), and could represent the future recommended ap-
proach. Along this line, the introduction of screening stool 
tests for ova and intestinal parasites should be considered 
in Sub Saharan and Syrian refugees, because of the high 
prevalence recently reported in these populations (Lifson 
et al., 2002; Garg et al., 2005; Mockenhaupt et al., 2016). 
Therefore, a European concerted action or network may 
be needed to collect these data and share knowledge to im-
prove the clinical care of these people. This applies in par-
ticular to our National Health Service, where a consistent 
margin for improvement may be detected from the pres-
ent report. A correct migration policy should also include 
the opportunity for prompt diagnosis and appropriate and 
timely treatment.
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